Key facts
- This page summarizes Wayne Burris's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2022, 16:23.
Wayne Burris - 31 May 2022 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)
- Reporting relationship
- Director
- Issuer ticker
- AXDX
- Reported as of
- 31 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2022, 16:23:55 UTC
- Prior SEC filing
- 08 Feb 2022
- Next SEC filing
- 08 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Reichling, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wayne Burris filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 02 Jun 2022.
Change
- Previous filing in this sequence was filed on 08 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXDX
transaction
Derivative
Employee Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +98,101
- Change %
- Price
- $0.000000
- Shares after
- 98,101
- Date
- 31 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 98,101
- Exercise price
- Footnotes
- F1, F2, F3
AXDX
transaction
Derivative
Employee Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +41,958
- Change %
- Price
- $0.000000
- Shares after
- 41,958
- Date
- 31 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,958
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Footnote F2
The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors.
Footnote F3
Not applicable.
Footnote F4
The restricted stock units vest equally each year for 5 years, with the first installment vesting on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.